logo
If you have a high VO2 max score, you could live longer. I took a class to boost mine — and finally found a way to make cardio fun.

If you have a high VO2 max score, you could live longer. I took a class to boost mine — and finally found a way to make cardio fun.

Yahoo15-07-2025
VO2 max is a buzzy measure of heart health and fitness.
I tried a class that promised to boost my VO2 max through cardio and breathwork.
I don't typically do cardio, and I realized taking classes could help me make it a habit.
I have a strange question, but stay with me: Have you ever thought about how long you can run without breathing through your mouth? In a dark basement in central London I recently discovered that, for me, the answer is: Not for very long.
Apparently, that means my VO2 max, or ability to send oxygenated blood to my muscles, and how well my muscles can use that oxygen during intense exercise, is quite low.
Translation: I'm unfit.
I do low-impact strength training like yoga and pilates most days, but no cardio. I've tried to get into running, but it never sticks, and I find cardio machines boring.
I learned specifically how bad I am at cardio at V02:MAXED, a new class at London's GymBox. I knew one session wouldn't transform my health, but I was interested to try the first class I'd seen marketed around VO2 max.
I wondered if exercising with a specific goal might motivate me to finally form a cardio habit, and if the class — and the nose strips we had to wear while working out — was just a fad.
Once the preserve of high-level athletes, in recent years, VO2 max has become a buzzy measure of cardiovascular fitness among runners, fitness competition enthusiasts, and health optimization bros. People are obsessed with it because it's said to be a strong predictor of longevity.
As I'm not an endurance athlete, my low score may not seem like a big deal, but having a high VO2 max is linked to a longer life, and a reduced risk of conditions including cardiovascular disease, cancer, and diabetes.
I don't care that I can't run five kilometers in under 30 minutes, but I do care about staying active and healthy as I age.
To increase your VO2 max, you have to do a mixture of shorter high-intensity and longer, easier workouts. VO2:Maxed is a 16-week course where clients train at a range of intensities. The class I did was the fourth in the series.
Feeling nervous about entering a gym that uses the words "gnarly," "sadistic," and "savage" to describe some of its classes, I descended the staircase from the reception area to the dimly lit bodybuilder's playground below with trepidation.
In the 50-minute class, we repeated three-minute sets on a stroke machine (ski or rower) and a cycle machine (bike or treadmill), with 45-second breaks in between. I used a ski machine and an assault bike.
What made the class unique was the breathwork. Our instructor, Firas Iskandarani, a Hyrox and Crossfit coach, explained that we should aim to breathe through our noses for most of the class. He called this type of breathing "gear one," and breathing in through the nose and out through the mouth "gear two."
We were told to note when we had to "switch gears." Iskandarani said this should happen after around 90-seconds to two-minutes, but I struggled to get to one minute.
As a rough guide, the longer you can stay in gear one, the higher your VO2 max is likely to be, he said. The idea is that, over time, you will need to switch gears less quickly, which indicates your aerobic capacity has increased.
About halfway through the class, we were given nasal strips to stick on the fleshy part of our noses, and encouraged to notice if it helped us stay in gear one for longer.
It's thought that widening the nasal canal could help to increase endurance by allowing more air through the nose. But one 2020 meta-analysis published in the European Archives of Oto-Rhino-Laryngology found that wearing a nasal strip while exercising didn't improve VO2 Max or heart rate. Still, lots of runners and athletes swear by them, like the elite tennis player Carlos Alcaraz, who wears them during his matches.
I felt that the nasal strip helped a little, but it kept peeling off as my nose got sweaty.
Nasal breathing is not directly linked to improving VO2 max, but is thought to help the body use oxygen more efficiently.
It also encourages you to stay in Zone 2, or at 60-70% of your maximum heart rate, while you're exercising. Your muscles have more access to oxygen in Zone 2, making it an effective way to increase aerobic endurance.
Once you enter Zone 3, 70% to 80% of your max heart rate, you're moving at an intensity that's too much for the available oxygen supply, which causes you to get out of breath.
I found there was a lot to remember and focus on in this class: not only understanding the different gears, but trying to stay in gear one while checking the clock to see when I started mouth breathing.
All of this mental arithmetic was required on top of the three-minute sets of cardio, which, I think is fair to say, is a long time. My mind kept wandering and I kept accidentally mouth breathing before I'd actually reached my threshold.
It was also tricky to go at a slow enough pace to stay in gear one for even a minute. After about thirty seconds I started to lose my breath. I suppose that tells me I have some work to do in this area.
That being said, I wasn't huffing and puffing or red in the face afterwards like I usually am after a 35-minute run. But my arms did get very tired from pulling the ropes on the ski machine and moving the handles on the assault bike back and forth.
If I did this class again I would pace myself better so that I wouldn't get out of breath so quickly. But I think for a cardio beginner like me, it was a little too technical and advanced.
Iskandarani said that part of the demand for the class came from Hyrox fans and CrossFitters, who are already pretty fit and looking to increase their endurance for competitions.
But I found doing cardio in such a structured way and with a group of people much more fun and motivating than doing it alone. Going forward, I think I'll stick to cardio classes rather than running every once in a while, getting bored, and trying again when enough time has passed for me to forget how arduous I found it.
By focusing on my breath, it became apparent that my cardiovascular fitness is lower than I'd like, and I'm only 28. I wondered how it would inevitably deteriorate over time, and if I'm struggling to get through a class like this now, it's only going to get harder when I'm in my 50s, let alone 80s.
As for the VO2 max workout, I don't think it was the right cardio class for me, but it's motivated me to continue my search. Anyone for Zumba?
Read the original article on Business Insider
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand
Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand

Yahoo

time18 minutes ago

  • Yahoo

Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand

Acquisition strengthens Obagi Medical's product portfolio with proven, scientifically backed, injectable portfolio New products position Obagi Medical at the forefront of health, beauty and aesthetics convergence LONDON, July 23, 2025 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) ('Waldencast'), a global multi-brand beauty and wellness platform, today announced that it has acquired Novaestiq Corp. (Novaestiq), a growth-oriented aesthetic and medical dermatological innovations company, as well as the U.S. rights to the Saypha® line of hyaluronic acid (HA) injectable gels. The strategic acquisition expands Obagi Medical's offerings beyond U.S. medical-grade skincare, a market projected to be $2.2 billion by 2029, into the growing U.S. dermal filler market, projected to reach $2 billion in market size by 2029, effectively doubling its addressable market.1 The move marks a pivotal step in positioning Obagi Medical as an industry leader in integrated skincare and aesthetic solutions. 'We are excited to further diversify Obagi Medical's portfolio of medical-grade skincare with consumer centric, in-office injectable procedures through the introduction of the Obagi Medical Saypha® ChIQ™ and MagIQ™ lines of injectable HA gels,' said Michel Brousset, Co-Founder and CEO of Waldencast. 'Adding proven products into our portfolio increases our addressable market and allows us to deliver solutions for professionals and patients seeking both skincare and aesthetic treatments, all under the trusted Obagi Medical brand.' Obagi Medical's philosophy advocates for a holistic, science-driven approach where potent skincare and professional procedures work in tandem to achieve and maintain optimal skin health and a youthful appearance. These injectable products will play a pivotal role in the evolution of Obagi Medical into an end-to-end, synergistic solution that integrates medical-grade skincare with aesthetic treatments to deliver enhanced outcomes, prolonged results, and greater patient satisfaction. Beyond the two current offerings, the Novaestiq transaction provides access to a future pipeline of novel injectables in North America. Saypha®,2 currently undergoing U.S. Food and Drug Administration (FDA) approval, is recognized globally as a proven, safe and efficacious HA injectable with high levels of patient satisfaction. The new Obagi Medical injectable portfolio is supported by an industry-leading clinical program that reflects the brand's commitment to science-backed innovation. Core pivotal studies are more than twice the size of typical nasolabial fold (NLF) and midface trials and include the highest representation of Fitzpatrick Skin Types I, V, and VI – underscoring Obagi Medical's mission to provide effective solutions for all skin types and tones. Saypha® is distinguished by its proprietary technology delivering advanced HA treatments through a stable 3D matrix designed to provide natural-looking results with optimally balanced gel characteristics. This technology powers a portfolio of clinically proven products that lead in multiple performance categories including high HA content at injection, ideal gel distribution, and consistent injection force and swelling behavior. Saypha®, a product of Croma-Pharma GmbH, is developed and manufactured in Austria and marketed in over 80 countries, leveraging 40 years of expertise in HA-based treatments with more than 110 million syringes produced. This global reach and deep market insight allow for the delivery of trusted, personalized care to patients and professionals worldwide. 'We believe that great results start with great skincare and are perfected with great after care,' said Dr. Suzan Obagi, Chief Medical Director at Obagi Medical. 'By combining Obagi Medical skincare with injectable procedures under the guidance of a qualified professional, patients can achieve more significant, longer-lasting, and natural-looking results. This acquisition also allows our professionals to offer patients more personalized, higher quality and safer products that their customers are looking for.' Obagi Medical's vision is to become the #1 Dermatological Mega Brand uniquely serving all the needs of physicians, patients and consumers globally. It is already the fastest-growing U.S. professional-skincare brand among the top ten in its category.3 This momentum is powered by a three-pronged strategy: anchoring products in dermatological science, introducing breakthrough innovations, and expanding its global reach. Brousset added, 'We are thrilled to introduce this new offering that will strengthen Obagi Medical's market position, drive innovation, and create new growth opportunities in our fast-evolving industry. We see an accelerating global convergence of health, beauty, and aesthetics – an intersection where Obagi Medical is uniquely positioned to lead. We also plan to leverage this acquisition to expand Obagi Medical's footprint.' Transaction DetailsUnder the terms of the definitive agreement relating to the transaction, Waldencast has agreed to acquire Novaestiq in exchange for (1) certain amount of cash payable at closing, (2) certain additional ongoing royalties based on net sales of Saypha® products, and (3) the contingent issuance of Waldencast class A shares (equal to approximately 7% of Waldencast's fully diluted class A shares), based on the receipt of FDA approval relating to the Saypha® products (triggering the issuance of 3,273,000 Waldencast class A shares) and the achievement of cumulative net revenue thresholds of (a) $100 million (triggering the issuance of an additional 3,273,000 Waldencast class A shares) and (b) $200 million (triggering the further issuance of 3,273,000 Waldencast class A shares), respectively, reflecting meaningful long-term commercial targets, with (a) and (b) being earnable until June 20, 2031. The details of the transaction will be summarized in more detail in a Form 6-K that Waldencast will file with the U.S. Securities and Exchange Commission (the 'SEC') following this press release. About WaldencastFounded by Michel Brousset and Hind Sebti, Waldencast's ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast's vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand's distinct DNA. The first step in realizing its vision was the business combination with Obagi Medical and Milk Makeup. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: . About Obagi MedicalObagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024,3 Obagi Medical empowers individuals to achieve healthy, beautiful skin. More information about Obagi is available on the brand's website, 1In preparing for this transaction, Waldencast engaged management consulting services from a reputed global consulting firm. 2Saypha® products are not approved medical devices, and each product has a premarket approval (PMA) application under review by the FDA. 3Among the Top 10 Professional Skin Care Brands in the U.S., according to Kline's 2024 Global Professional Skin Care Series (China, Europe and the U.S.). AdvisorsHolland & Knight LLP is serving as Waldencast's legal advisor, with support from Skadden, Arps, Slate, Meagher & Flom LLP. Experium Capital Advisers is serving as Waldencast's financial advisor. Forward-Looking StatementsThis press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the intended benefits of the transaction with Novaestiq, the ability to obtain FDA approval for Saypha®, the contingent issuance of Waldencast class A shares, and the growth strategies of Waldencast, including Obagi Medical and Novaestiq. These forward-looking statements generally are identified by the words 'estimates,' 'projects,' 'expects,' 'anticipates,' 'forecasts,' 'plans,' 'intends,' 'believes,' 'seeks,' 'may,' 'will,' 'would,' 'should,' 'future,' 'propose,' 'target,' 'goal,' 'objective,' 'outlook' and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of Waldencast, Obagi Medical and Novaestiq that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include, but are not limited to: (i) the inability to recognize the anticipated benefits of the transaction; (ii) the inability to obtain FDA approval for one or both of the Saypha® products; (iii) the general impact of geopolitical events, including the impact of current wars, conflicts and other hostilities; (iv) the overall economic and market conditions, sales forecasts and other information about Waldencast's possible or assumed future results of operations or our performance; (v) changes in general economic conditions; (vi) the impact of any international trade or foreign exchange restrictions, the imposition of new or increased tariffs, foreign currency exchange fluctuations; (vii) that the price of Waldencast's securities may be volatile due to a variety of factors, including Waldencast's, Obagi Medical's or Novaestiq's inability to implement their business plans; and (viii) the ability to implement Waldencast's strategic initiatives and continue to innovate Obagi Medical's existing products and anticipate and respond to market trends and changes in consumer preferences. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the 'Risk Factors' section of Waldencast's Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on March 20, 2025, or in other documents that may be filed or furnished by Waldencast from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Waldencast assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Contacts InvestorsICRinvestors@ MediaICRwaldencast@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Billion euro deal: Sanofi buys UK biotech company to expand respiratory vaccine portfolio
Billion euro deal: Sanofi buys UK biotech company to expand respiratory vaccine portfolio

Yahoo

timean hour ago

  • Yahoo

Billion euro deal: Sanofi buys UK biotech company to expand respiratory vaccine portfolio

In the race to develop next-generation respiratory virus vaccines, French pharmaceutical company Sanofi has agreed to buy Vicebio Ltd., a privately-held biotechnology company headquartered in London, UK. Sanofi said there will be an initial cash payment of $1.15bn (€980 million) for the deal, 'with potential milestone payments of up to $450 million based on development and regulatory achievements'. 'We are excited to join Sanofi', said Emmanuel Hanon, Chief Executive Officer at Vicebio, in a statement. 'Their global scale and deep expertise in vaccine development provide the ideal environment to fully realise the potential of our innovative technology." With the acquisition, Sanofi gets Vicebio's early-stage combination vaccine candidate for two respiratory viruses, the respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). Respiratory infections, affecting millions globally, often appear as cold-like illnesses that could, in severe cases, lead to pneumonia. In respiratory medication, Sanofi already has several vaccines in its portfolio against flu and RSV prevention; this latest acquisition adds a non-mRNA vaccine to its pipeline. mRNA technology is relatively new for vaccines. It teaches the body how to make a protein that triggers an immune response to protect against a specific virus, instead of using a weakened or inactivated germ to trigger this reaction. With the current deal, Sanofi also gets access to Vicebio's Molecular Clamp technology, which stabilises viral proteins in their native shape, triggering a more effective immune response. This technology is expected to speed up vaccine development and simplify manufacturing and distribution. Related EU pharma chief calls for European Nasdaq to boost biotech innovation Doliprane-maker Sanofi confirms exclusive talks with US firm CD&R 'This acquisition furthers Sanofi's dedication to vaccine innovation with the potential to develop next-generation combination vaccines that could provide protection to older adults against multiple respiratory viruses with a single immunisation," said Jean-François Toussaint, global head of research and development vaccines at Sanofi. The transaction is expected to close by the end of 2025, and will not have a significant impact on Sanofi's financial guidance for 2025. The pharma giant's share price was down around 0.4% before 11:00 CEST in Paris. Sign in to access your portfolio

Long COVID Gene Variants: A Step Toward a Diagnostic Test?
Long COVID Gene Variants: A Step Toward a Diagnostic Test?

Medscape

time2 hours ago

  • Medscape

Long COVID Gene Variants: A Step Toward a Diagnostic Test?

A large-scale global study has identified genetic variants that are risk factors for long COVID, a discovery that helps researchers better understand the biological systems involving the disease and one small, early step toward the elusive goal of developing a long COVID diagnostic test. International researchers with the Long COVID Host Genetics Initiative used data from 33 independent studies and 19 countries across North America, Europe, the Middle East, and Asia to analyze the genomes of nearly 16,000 patients with long COVID, representing populations from six genetic ancestries. Nearly 1.9 million controls were included in the genome-wide association study, a research method that scans complete sets of DNA to identify genetic variations associated with a specific trait or disease. Genetic variants found in the FOXP4 gene had a statistically significant risk linked to long COVID, the study, published in Nature Genetics , found. The FOXP4 gene is known to impact lung function, and its expression levels were higher in those with long COVID than in controls. In addition, the risk variants had a consistent effect across different ancestries. The researchers also found a causal relationship between a SARS-CoV-2 infection and long COVID and an additional causal risk between infections severe enough to require hospitalization and long COVID. Researchers also analyzed possible connections between variants associated with long COVID and those linked to other diseases and conditions. Scientists said the overall findings provided evidence that was consistent with long COVID research that suggests both individual genetic variants and environmental risk factors contribute to disease risk. The findings also provide genetic proof linking abnormal lung physiology and the development of long COVID, the authors concluded; however, they noted that long COVID symptoms are not only limited to lung function and may include fatigue and cognitive dysfunction as well. The study's co-author, Hanna Ollila, PhD, with the Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland, underscored that the newly discovered genetic variants were not predictive for clinical tests or personal disease risk. 'The findings from our study, and from genome-wide association studies in general, tell about biological mechanisms behind a disease. This can then help to understand the disease better. For example, is it a disease neuronal, immune, metabolic, and so on?' said Ollila, who is also a researcher with the Department of Anesthesia and Center for Genomic Medicine at Massachusetts General Hospital, Boston. There are still many steps between these types of discoveries and the development of a diagnostic test, she explained, since these types of genetic variants do not function like high-impact variants such as the BRCA mutations in breast cancer. 'In other words, they do not strongly predict whether someone will develop long COVID at the individual level,' Ollila said. 'Instead, they highlight the biological systems involved in the disease. In this case, our findings point to immune pathways related to lung function.' Ollila explained that genetics can guide diagnostic development by pointing to underlying mechanisms, which may then help identify biomarkers in blood or other tissues. These biomarkers could eventually contribute to diagnostic tools, but it is a process that takes time and collaboration and often depends on progress across several fields of research including imaging and clinical phenotyping. Researchers hope that when larger sample sizes become available for bigger studies, the analyses and understanding of the correlations will become more precise, bringing more understanding and clarity on genetic risk factors, biological mechanisms, and biomarkers that could someday help with disease diagnosis. 'We are likely still several years away, and possibly even a decade or more, from having a clinically useful diagnostic test based on genetic or biological markers for long COVID,' said Ollila. 'That said, progress is accelerating thanks to the growing number of well-characterized cohorts and international collaborations. While these genetic findings are not yet ready for clinical application, they are an important step toward understanding long COVID, its relationship with other diseases, and the disease mechanisms that modulate risk for long COVID.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store